C-erbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer

Oncology Reports

Volumn 18, Issue 1, 2007, Pages 121-126

  Logullo, Angela F ^a   Lopes, Andreia B G ^b   Nonogaki, Suely ^c   Soares, Fernando A ^b   Netto, Mário Mourão ^b   Nishimoto, Inês N ^b   Brentani, M Mitzi ^d  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b IM IN JK) Inst Do C   (Brazil)

^c INSTITUTO ADOLFO LUTZ   (Brazil)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Breast carcinoma; c erbB 2; Disease free survival; Galectin 3; Immunohistochemistry; p53; Prognosis; Survival; T1N0M0

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GALECTIN 3; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST TUMOR; CANCER STAGING; ENZYME IMMUNOASSAY; FEMALE; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; MIDDLE AGED; MORTALITY; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; GALECTIN 3; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34548024201     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.18.1.121     Document Type: Article

References (27)

1. Ernster VL, Ballard-Barbash R, Barlow WE, Zheng Y, Weaver DL, Cutter G, Yankaskas BC, Rosenberg R, Carney PA, Kerlikowske K, Taplin SH, Urban N and Geller BM: Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst 94: 1546-1554, 2002. (Pubitemid 35277278)
2. Tabar L, Duffy SW, Vitak B, Chen HH and Prevost TC: The natural history of breast carcinoma: what have we learned from screening? Cancer 86: 449-462, 1999. (Pubitemid 29347407)
3. Joensuu H, Pylkkanen L and Toikkanen S: Late mortality from pT1N0M0 breast carcinoma. Cancer 85: 2183-2189, 1999. (Pubitemid 29215557)
4. Westenend PJ, Meurs CJ and Damhuis RA: Tumour size and vascular invasion predict distant metastasis in stage I breast cancer. Grade distinguishes early and late metastasis. J Clin Path 58: 196-201, 2005. (Pubitemid 40193807)
5. Hanrahan EO, Valero V, Gonzalez-Angulo AM and Hortobagyi GN: Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0): a review of the literature. J Clin Oncol 24: 2113-2122, 2006. (Pubitemid 46628472)
6. Liu FT and Rabinovich GA: Galectins as modulators of tumour progression. Nat Rev Cancer 5: 29-41, 2005.
7. Castronovo V, Van Den Brule FA, Jackers P, Clausse N, Liu FT, Gillet C and Sobel ME: Decreased expression of galectin-3 is associated with progression of human breast cancer. J Pathol 179: 43-48, 1996. (Pubitemid 26182865)
8. Idikio H: Galectin-3 expression in human breast carcinoma: correlation with cancer histologic grade. Int J Oncol 12: 1287-1290, 1998.
9. Joensuu H, Isola J, Lundin M, Salminen T, Holli K, Kataja V, Pylkkanen L, Turpeenniemi-Hujanen T, von Smitten K and Lundin J: Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide populationbased study. Clin Cancer Res 9: 923-930, 2003. (Pubitemid 36323694)
10. Linjawi A, Kontogiannea M, Halwani F, Edwardes M and Meterissian S: Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer. J Am Coll Surg 198: 83-90, 2004. (Pubitemid 38201092)
11. Lee WY, Su WC, Lin PW, Guo HR, Chang TW and Chen HH: Expression of S100A4 and Met: potential predictors for metastasis and survival in early-stage breast cancer. Oncology 66: 429-438, 2004.
12. Colleoni M, Rotmensz N, Peruzzotti G, Maisonneuve P, Viale G, Renne G, Casadio C, Veronesi P, Intra M, Torrisi R and Goldhirsch A: Minimal and small size invasive breast cancer with no axillary lymph node involvement: the need for tailored adjuvant therapies. Ann Oncol 15: 1633-1639, 2004. (Pubitemid 39562603)
13. Gaudin JC, Arar C, Monsigny M and Legrand A: Modulation of the expression of the rabbit galectin-3 gene by p53 and c-Ha-ras proteins and PMA. Glycobiology 7: 1089-1098, 1997. (Pubitemid 28015798)
14. Mackay A, Jones C, Dexter T, Silva RL, Bulmer K, Jones A, Simpson P, Harris RA, Jat PS, Neville AM, Reis LF, Lakhani SR and O'Hare MJ: cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells. Oncogene 22: 2680-2688, 2003. (Pubitemid 36605615)
15. O'Driscoll L, Linehan RM, Kennedy S, Cronin D, Purcell R, Glynn SW, McDermott ED, Hill AJ, O'Higgins N, Parkinson M and Clynes M: Lack of prognostic significance of survivin, survivin-deltaEx3, survivin-2B, galectin-3, bag-1, bax-alpha and MRP-1 mRNAs in breast cancer. Cancer Lett 201: 225-236, 2003. (Pubitemid 37357172)
16. Jones C, Mackay A, Grigoriadis A, Cossu A, Reis-Filho JS, Fulford L, Dexter T, Davies S, Bulmer K, Ford E, Parry S, Budroni M, Palmieri G, Neville AM, O'Hare MJ and Lakhani SR: Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Cancer Res 64: 3037-3045, 2004. (Pubitemid 38581402)
17. Elston CW and Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-410, 1991.
18. van de Vijver MJ: Biological variables and prognosis of DCIS. Breast 14: 509-519, 2005.
19. Moiseeva EV, Rapoport EM, Bovin NV, Miroshnikov AI, Chaadaeva AV, Krasilshschikova MS, Bojenko VK, Bijleveld C, van Dijk JE and Den Otter W: Galectins as markers of aggressiveness of mouse mammary carcinoma: towards a lectin target therapy of human breast cancer. Breast Cancer Res Treat 91: 227-241, 2005. (Pubitemid 40896569)
20. Shekhar MP, Nangia-Makker P, Tait L, Miller F and Raz A: Alterations in galectin-3 expression and distribution correlate with breast cancer progression: functional analysis of galectin-3 in breast epithelial-endothelial interactions. Am J Pathol 165: 1931-1941, 2004. (Pubitemid 39578372)
21. Califice S, Castronovo V, Bracke M and van den Brule F: Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs. tumor promotion of cytoplasmic galectin-3. Oncogene 23: 7527-7536, 2004. (Pubitemid 39389694)
22. Honjo Y, Inohara H, Akahani S, Yoshii T, Takenaka Y, Yoshida J, Hattori K, Tomiyama Y, Raz A and Kubo T: Expression of cytoplasmic galectin-3 as a prognostic marker in tongue carcinoma. Clin Cancer Res 6: 4635-4640, 2000. (Pubitemid 32110398)
23. van den Brule FA, Waltregny D, Liu FT and Castronovo V: Alteration of the cytoplasmic/nuclear expression pattern of galectin-3 correlates with prostate carcinoma progression. Int J Cancer 89: 361-367, 2000. (Pubitemid 30620290)
24. Lotz MM, Andrews CW Jr, Korzelius CA, Lee EC, Steele GD Jr, Clarke A and Mercurio AM: Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its nuclear localization are associated with the neoplastic progression of colon carcinoma. Proc Natl Acad Sci USA 90: 3466-3470, 1993. (Pubitemid 23111387)
25. Park JW, Voss PG, Grabski S, Wang JL and Patterson RJ: Association of galectin-1 and galectin-3 with Gemin 4 in complexes containing the SMN protein. Nucleic Acids Res 29: 3595-3602, 2001. (Pubitemid 32898773)
26. Nakahara S, Oka N and Raz A: On the role of galectin-3 in cancer apoptosis. Apoptosis 10: 267-275, 2005. (Pubitemid 40603482)
27. Nakahara S, Oka N, Wang Y, Hogan V, Inohara H and Raz A: Characterization of the nuclear import pathways of galectin-3. Cancer Res 66: 9995-10006, 2006. (Pubitemid 44672052)